Rein Therapeutics, Inc. Retained Earnings
Rein Therapeutics, Inc. (RNTX) had Retained Earnings of -$413.48 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$413.48M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$407.11M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$401.27M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$369.30M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$413.48M 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$407.11M 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$401.27M 10-Q · filed 2026-08-14 |
| 2025-09-30 | -$369.30M 10-Q · filed 2025-11-14 |
| 2025-06-30 | -$363.72M 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$356.90M 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$351.40M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$310.42M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$304.57M 10-Q · filed 2024-08-14 |
| 2024-03-31 | -$295.63M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$288.52M 10-K · filed 2025-04-07 |
| 2023-09-30 | -$281.18M 10-Q · filed 2023-10-13 |
| 2023-06-30 | -$279.35M 10-Q · filed 2023-08-11 |
| 2023-03-31 | -$277.56M 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$272.79M 10-K · filed 2024-04-15 |
| 2022-09-30 | -$268.24M 10-Q · filed 2022-11-01 |
| 2022-06-30 | -$261.87M 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$253.88M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$245.46M 10-K · filed 2023-03-20 |
| 2021-09-30 | -$238.66M 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$231.95M 10-Q · filed 2021-08-11 |
| 2021-03-31 | -$226.27M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$219.29M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$214.30M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$209.27M 10-Q · filed 2020-08-05 |
| 2020-03-31 | -$204.88M 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$198.13M 10-K · filed 2021-03-24 |
| 2019-09-30 | -$190.90M 10-Q · filed 2019-11-07 |
| 2019-06-30 | -$183.15M 10-Q · filed 2019-08-06 |
| 2019-03-31 | -$175.98M 10-Q · filed 2019-05-08 |
| 2018-12-31 | -$168.49M 10-K · filed 2020-03-30 |
| 2018-09-30 | -$161.46M 10-Q · filed 2018-11-07 |
| 2018-06-30 | -$154.03M 10-Q · filed 2018-08-07 |
| 2018-03-31 | -$144.53M 10-Q · filed 2018-05-09 |
| 2017-12-31 | -$136.95M 10-K · filed 2019-03-29 |
| 2017-09-30 | -$130.08M 10-Q · filed 2017-11-09 |
| 2017-06-30 | -$123.82M 10-Q · filed 2017-08-10 |
| 2016-12-31 | -$114.34M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |